High-dose Flu Vaccine in Older Adults
Next year, the ACIP may be recommending high-dose flu vaccine for those ≥ 65 years of age, based on the results of a new study. High-dose trivalent inactivated vaccine was compared to standard-dose inactivated vaccine to evaluate flu protection in those ≥ 65 years of age. The high-dose strain has four times the antigen of the standard dose. Nearly 32,000 adults in the United States and Canada were randomized to standard-dose or high-dose trivalent flu vaccine. In the intention-to-treat analysis, 1.4% of high-dose recipients and 1.9% of low-dose recipients developed laboratory-confirmed influenza (relative efficacy, 24.2%; 95% confidence interval, 9.7-36.5). Antibody titers were significantly higher in the high-dose group, and adverse events were slightly higher in the high-dose group. The authors conclude that among those ≥ 65 years, high-dose trivalent flu vaccine induced higher antibody responses and better protection against laboratory-confirmed influenza compared to standard-dose vaccine (N Engl J Med 2014;371:635-645).
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.